Diagnostic testing company Singulex postpones $70 million IPO

By
A A A

Singulex, which provides diagnostic testing for cardiovascular disease in a non-acute setting, postponed its IPO on Wednesday. The Alameda, CA-based company was founded in 1997 and booked $38 million in sales for the 12 months ended 6/30/2012. UBS Investment Bank and Piper Jaffray were set to be the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: SGLX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Save Money in the Kitchen
Save Money in the Kitchen           

Stocks

Referenced

Most Active by Volume

89,873,982
  • $17.67 ▼ 1.28%
64,126,835
  • $11.37 ▼ 7.49%
54,368,666
  • $3.84 ▼ 1.03%
49,751,147
  • $34.32 ▲ 0.09%
48,491,927
  • $3.10 ▼ 9.88%
43,509,749
  • $14.55 ▲ 1.11%
42,710,239
  • $122.77 ▼ 1.39%
41,617,381
  • $28.35 ▲ 1.03%
As of 7/27/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com